Pharmaceutical CDMO Selection: Due Diligence Guide

Why Pharmaceutical CDMO Selection Decides Whether a Startup Ships on Time

Most pharmaceutical startups outsource manufacturing, so the contract partner ends up controlling their timeline, cost, and inspection risk. Under FDA expectations, the product owner remains accountable for quality, and the owner's quality unit must be able to approve or reject every batch. A partner with weak quality systems therefore puts the owner's application, batch releases, and reputation at risk. Selection is best treated as a structured pharma contract manufacturing due diligence project, not a price comparison.

• Timeline control — the partner's capacity, scheduling, and right-first-time record set how quickly clinical and commercial batches arrive.
• Regulatory exposure — a pre-approval inspection of the manufacturing site can delay an application if the site has unresolved compliance issues.
• IP exposure — your process know-how moves into someone else's facility, so ownership and confidentiality terms matter from day one.
• Switching cost — changing CDMOs after transfer means repeating transfer and validation work and filing a site change with regulators.

Before comparing partners, it helps to know which type of contract organization fits your stage, which the next section clarifies.

CDO, CMO, and CDMO: What Each Contract Model Covers

Contract organizations sell different scopes of work under similar acronyms, and mixing them up leaves gaps that nobody owns. A contract development organization designs and optimizes the formulation and process, while a contract manufacturing organization makes batches to a process you supply. A CDMO combines development and manufacturing under one roof, as this overview of the contract manufacturing organization model describes. Which model fits depends on how much validated process knowledge you already own.

Once the model is clear, the next question is whether a specific facility can actually make your dosage form at your scale.

Matching Dosage Form, Scale, and Development Stage to CDMO Capability

A CDMO that excels at oral solids can be the wrong choice for sterile injectables, and the reverse is equally true. Capability fit covers dosage form, containment level, batch-size range, analytical depth, and the regulatory standard the facility is built to meet. Stage matters too, because FDA's guidance on CGMP for Phase 1 investigational drugs allows stage-appropriate controls, while later phases and commercial supply demand progressively fuller compliance. Choosing a partner that can grow with the product avoids a second selection and a second technology transfer.

• Dosage-form expertise — verify demonstrated experience with your form, such as oral solid, semisolid, liquid, or sterile, not just equipment on a brochure.
• Containment and segregation — highly potent or sensitizing actives need dedicated or well-segregated suites, with evidence that cross-contamination is controlled.
• Batch-size range — confirm the facility can make both your development lots and your projected commercial lots, or has a defined scale-up path.
• Analytical capability — in-house method development, validation, and stability testing shorten timelines and reduce hand-offs between organizations.
• Regulatory standing for target markets — confirm inspection history with the agencies that matter for your market, such as FDA, EMA, or your national regulator.

Capability on paper still has to be proven by the partner's quality systems and inspection record, which are the non-negotiables covered next.

Quality Systems and Inspection History: The Non-Negotiables

Equipment and price can be negotiated, but a weak quality system cannot be fixed by the customer. The clearest evidence is the facility's regulatory record, meaning inspection outcomes, observations, and how promptly the site closed them. FDA publishes warning letters and makes inspection classification data publicly searchable, which lets you verify claims before an audit is even scheduled. Treat any reluctance to share inspection history, or a pattern of repeat observations, as a serious warning sign.

• Inspection outcomes — request recent regulatory inspection reports and the site's responses to observations, not just a summary of clean audits.
• Independent quality unit — the quality unit should have authority to reject batches, free from production and sales pressure.
• Data integrity — look for controlled access, audit trails, and contemporaneous recording consistent with ALCOA+ principles.
• Deviation and CAPA discipline — closed-out deviations, root-cause investigations, and effectiveness checks show whether problems are actually fixed.
• Change control — the partner must notify you before changing materials, equipment, or process steps that affect your product.

Documents describe intent, however, so the only way to confirm actual practice is to observe the operation directly through an audit.

Running a CDMO Audit: What to Verify on the Floor

An audit turns a partner's written procedures into observed behavior, which is why no startup should sign a manufacturing agreement without one. A paper audit using a questionnaire screens the shortlist cheaply, and an on-site qualification audit then confirms what the documents claim. Auditors should trace a real batch record end to end, rather than accept a curated walk-through of the cleanest area. Independent CDMO audit consulting services add value because experienced auditors know which findings signal a systemic problem.

• Batch record trace — follow one recent batch from raw material receipt to release and confirm every entry is contemporaneous and reviewed.
• Cleaning validation and cross-contamination — in multi-product facilities, check residue limits and swab evidence. Our guide to pharmaceutical cleaning validation and residue limits explains what defensible evidence looks like.
• Equipment qualification and calibration — verify current qualification status and calibration records for the equipment that would run your process.
• Raw material control — check supplier qualification, identity testing, and quarantine practice for incoming materials and components.
• Laboratory practice — review out-of-specification handling, method validation, and stability chamber records.
• Personnel and training — confirm operators are trained on your specific process before your batches run.

A facility that passes the audit still needs your process moved into it accurately, which is the job of technology transfer.

Technology Transfer: Moving Your Process Into the CDMO

Technology transfer is the step where undocumented process knowledge either becomes usable on the manufacturing floor or gets lost. A structured transfer package, backed by dedicated CDMO technology transfer support, documents the formulation, critical process parameters, analytical methods, and the reasoning behind each setpoint. The receiving site then runs engineering batches to prove it can reproduce your product at scale before any validation batches are made. Our guide to pharmaceutical process validation from R&D to commercial covers how those early batches connect to formal validation.

1. Transfer package — assemble the formulation, process description, specifications, and analytical methods in a controlled, version-managed document set.
2. Gap assessment — compare your equipment and scale with the CDMO's equipment to identify parameters that need adjustment.
3. Analytical method transfer — demonstrate that the CDMO's laboratory obtains equivalent results with your methods before batches begin.
4. Engineering batches — run development-scale batches at the receiving site to confirm the process behaves as expected on its equipment.
5. Validation batches — execute the qualification runs that generate the evidence supporting commercial supply and regulatory filings.

Transfer only works when responsibilities are written down, which is exactly what the quality agreement and supply agreement are for.

Quality Agreements and Contract Terms That Protect the Product Owner

A CDMO relationship rests on two different documents, and each protects a different interest. The quality agreement assigns CGMP responsibilities between owner and contract facility, and FDA's guidance on quality agreements recommends keeping it separate from general business terms. The supply or manufacturing agreement covers the commercial side, including pricing, volumes, intellectual property, liability, and termination. Both documents matter, because a strong price with vague quality responsibilities leaves the owner exposed during an inspection.

• IP ownership — define ownership of your formulation and process know-how, and of any improvements made during transfer or optimization.
• Change notification — require advance written notice and approval rights for changes to materials, equipment, sites, or process steps.
• Audit rights — secure the right to audit on a schedule and for cause, including access to relevant records.
• Batch disposition — state clearly who reviews records, who releases product, and how failed batches and investigations are handled.
• Exit and transition — include termination provisions and assistance moving your process to another site.

Even well-drafted terms depend on the commercial model behind them, including how capacity is allocated when demand is tight.

Commercial Models, Capacity, and Supply Continuity

The commercial structure determines how much risk the owner carries when demand changes, so it deserves as much scrutiny as the technical scope. CDMOs commonly price either per project on a fee-for-service basis or through dedicated capacity or staffing commitments. Startups should ask how a client of their size is prioritized in the production schedule, and what happens when a larger customer competes for the same suite. Supply continuity planning, including raw material sourcing and a qualified second site, belongs in the contract from the start.

• Fee-for-service — pay per batch or project, which gives flexibility but less guaranteed capacity.
• Dedicated capacity — reserved suites or staff give schedule certainty, usually with minimum commitments or take-or-pay terms.
• Raw material responsibility — decide whether the CDMO or the owner qualifies and buys starting materials, and who bears shortages.
• Price escalation — check indexing clauses and how price changes with volume or raw material costs.
• Second-source planning — qualifying a backup site or alternative supplier early reduces single-point-of-failure risk.

With technical, quality, and commercial criteria all defined, a weighted scorecard turns them into a defensible comparison.

Scoring CDMO Candidates: A Weighted Due-Diligence Framework

Weighing CDMO selection criteria by instinct favors the best presentation, not the best fit, so a weighted scorecard keeps the decision defensible. Assign weights to criteria before you see any proposals, so pricing cannot quietly rewrite your priorities. Score each candidate on evidence you obtained yourself, such as inspection records and audit observations, not on claims in the sales deck. The table below shows the evidence to request and the warning signs for each criterion.

A scorecard identifies the strongest candidate, but running the whole selection as a sequenced program keeps it on schedule.

Building a CDMO Selection Program and Choosing an Advisory Partner

A CDMO selection that runs on ad hoc emails takes months longer than one run as a sequenced program with clear gates. The sequence below reflects how Global Formulation structures partner selection, audit support, and technology transfer for startups and manufacturers. Each step produces a document that supports the next, so evidence accumulates rather than being collected again.

1. Define requirements — write the target product profile, dosage form, batch scales, timeline, and regulatory market before contacting any CDMO.
2. Confidential information exchange — sign confidentiality agreements before sharing formulation or process details.
3. Shortlist by paper audit — send a standard questionnaire and request inspection history from several candidates.
4. On-site audit — audit the top two or three candidates, tracing batch records and reviewing quality systems.
5. Score and negotiate — apply the weighted scorecard, then negotiate the supply agreement and quality agreement in parallel.
6. Pilot transfer — begin with a limited-scope transfer and engineering batch before committing to a full program.

Startups often lack the in-house quality and technical staff to run these steps alone. Our guide to choosing a pharmaceutical formulation consultant as a startup explains how an independent contract development and manufacturing organization consultant can lead the audit and transfer work. Our guide to the pharmaceutical regulatory pathway under FDA, ICH, and USP covers the compliance context those contracts must support.

• Independence — an advisor paid by you, not commissioned by the CDMO, protects the objectivity of audit findings.
• Hands-on GMP experience — auditors and transfer leads should have worked inside manufacturing and quality units, not only in consulting.
• Formulation depth — the advisor should understand your dosage form well enough to challenge the CDMO's process assumptions.
• Regulatory literacy — familiarity with FDA, ICH, and quality-agreement expectations prevents contract terms from creating inspection gaps.

A pharmaceutical and healthcare formulation partner can also help decide which development activities belong inside the CDMO and which should stay under your own control. Global Formulation provides pharmaceutical CDMO selection support, audit preparation, technology transfer coordination, and formulation development for startups moving from lab to commercial supply.